Aesica Pharmaceuticals S.r.I. Implements Serialization System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aesica Pharmaceuticals S.r.I. Implements Serialization System

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 7

Aesica Pharmaceuticals S.r.l. has announced the launch of a QAD integrated serialization system at its site in Pianezza to comply with change from China’s Food and Drug Administration (CFDA). The new requirements brought forward by CFDA cut the serialization implementation deadline to from 12 months to three months.

In partnership with QAD, a provider of enterprise software solutions, Aesica reports that the company implemented a solution that assured serialization compliance for two pharmaceutical products for the Chinese market.

The new requirements are designed to maintain customer safety, while fighting drug counterfeiting, streamlining the recall process, and minimizing financial loss. The project involved upgrading and utilizing a serialization module developed in QAD Enterprise Applications that allows Aesica Pharmaceuticals S.r.I. to identify individual packaging down to the smallest sellable unit sizes and aggregate individual unit serial numbers as packages are bundled, boxed and placed on shipping pallets. Aesica Pianezza can seamlessly track and trace each single pack of medication and report serial numbers to the required government agencies for a small number of products once they have been produced and imported.

Source: Aesica Pharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here